Last reviewed · How we verify
Calcium renal calculus — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Osmoprep | sodium phosphate, monobasic, monohydrate | Salix Pharms | Calculi Dissolution Agent [EPC] | 2000-01-01 | ||
| Aloprim | ALLOPURINOL | Casper Pharma Llc | Xanthine Oxidase Inhibitor [EPC] | Xanthine dehydrogenase/oxidase | 1966-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
- — Aloprim · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Casper Pharma Llc · 1 drug in Calcium renal calculus
- Salix Pharms · 1 drug in Calcium renal calculus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Calcium renal calculus:
- Calcium renal calculus treatment updates — RSS
- Calcium renal calculus treatment updates — Atom
- Calcium renal calculus treatment updates — JSON
Cite this brief
Drug Landscape (2026). Calcium renal calculus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/calcium-renal-calculus. Accessed 2026-06-10.
Related
- Calcium renal calculus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing